aTyr Pharma
ATYR
36 hedge funds and large institutions have $53.1M invested in aTyr Pharma in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.72% less ownership
Funds ownership: 70.6% → 66.89% (-3.7%)
12% less funds holding
Funds holding: 41 → 36 (-5)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
49% less capital invested
Capital invested by funds: $105M → $53.1M (-$51.9M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
85% less call options, than puts
Call options by funds: $64K | Put options by funds: $436K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$765K |
| 2 |
TI
Telemetry Investments
New York
|
+$595K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$168K |
| 4 |
Renaissance Technologies
New York
|
+$145K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.67M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$906K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$578K |
| 4 |
Two Sigma Investments
New York
|
-$205K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$198K |
ATYR Hedge Fund Activity: Q2 2022 in Review
36 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q2 2022, worth a combined $53.1M — down 49% from $105M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATYR and 5 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Alyeska Investment Group, adding an estimated $765K. The largest seller was Deep Track Capital, cutting an estimated $2.67M.
- 36 institutional investors held aTyr Pharma (ATYR) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $53.1M of aTyr Pharma stock for Q2 2022, down 49% quarter-over-quarter.
- 5 funds opened new aTyr Pharma positions in Q2 2022 and 10 closed out, a net change of -5 holders.
- The largest aTyr Pharma buyer in Q2 2022 was Alyeska Investment Group, an estimated $765K added.
- The largest aTyr Pharma seller in Q2 2022 was Deep Track Capital, an estimated $2.67M sold.
Based on aggregated 13F filings for Q2 2022.